SCHEDULE 13G/A: Perceptive Advisors and Affiliates Disclose 4.5% Stake in Biodesix, Inc.

Perceptive Advisors LLC, along with its affiliates and Joseph Edelman, has disclosed a combined beneficial ownership of 4.5% in Biodesix, Inc., including common stock and exercisable warrants.

Summary

• Perceptive Advisors LLC, Joseph Edelman, Perceptive Credit Advisors LLC, PCOF EQ AIV IV, LP (Opportunity Fund), and Perceptive Credit Holdings IV, LP (Credit Fund) collectively reported beneficial ownership of 6,673,880 shares of Biodesix, Inc. common stock.
• This aggregate ownership represents 4.5% of Biodesix, Inc.'s outstanding common stock, based on 145,465,941 shares outstanding as of October 25, 2024.
• The Credit Fund directly holds 1,036,560 shares of common stock and 4,500,000 warrants to purchase additional shares.
• The warrants held by the Credit Fund include 3,000,000 exercisable at $1.0648 expiring November 21, 2032; 1,000,000 exercisable at $1.0648 expiring December 20, 2033; and 500,000 exercisable at $1.6254 expiring May 10, 2033.
• The Opportunity Fund directly holds 1,137,320 shares of common stock.
• The reporting persons have shared voting and dispositive power over their respective holdings.
• The warrants held by the Credit Fund can be fully exercised without exceeding the 9.9% beneficial ownership limit, indicating potential for increased stake.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The maintenance of a significant stake by a prominent investment group like Perceptive Advisors could be seen as mildly positive, indicating continued interest, but it does not provide performance or outlook information to warrant a strong sentiment score.

Positives

• A significant institutional investor, Perceptive Advisors, maintains a substantial stake in Biodesix, indicating continued interest or confidence in the company.
• The ability of the Credit Fund to exercise all of its warrants suggests flexibility in increasing their stake without breaching the 9.9% beneficial ownership threshold.

Risks

• The filing states that warrants may not be exercised if the Reporting Persons would beneficially own more than 9.9% of the Issuer's outstanding shares, which could limit their ability to increase their stake beyond this threshold.

Future Outlook

The document is a Schedule 13G filing, which primarily discloses beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Industry Context

This filing indicates a significant institutional investor's continued or adjusted stake in Biodesix, Inc., a company likely operating in the healthcare or biotechnology sector given its name. Such disclosures are common and reflect investment firms' portfolio adjustments based on their assessment of individual company prospects within their respective industries.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure of beneficial ownership and does not provide information suitable for direct comparison to industry-specific operational or financial benchmarks of comparable companies or projects. It solely details the ownership position of a specific investment group in Biodesix, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Perceptive Advisors may influence investor perception and potentially provide a degree of confidence or stability to the shareholder base.

Key Dates

Keywords

Biodesix Inc, Perceptive Advisors, Joseph Edelman, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Healthcare, Biotechnology